logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilipā€¦ read more

Healthcare

Biotechnology

45 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$5.11

Price

+3.86%

$0.19

$4.92

Previous Close

$4.94

Open

Premium

52w Discount
Market Cap

$255.500m

Small

Price/Earnings

4.2x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$400k

-

1y CAGR

+15.8%

3y CAGR

-1.3%

5y CAGR
Earnings

$82.350m

+229.2%

1y CAGR

+58.4%

3y CAGR

+57.1%

5y CAGR
EPS

$1.14

+173.6%

1y CAGR

+88.9%

3y CAGR

+85.2%

5y CAGR
Book Value

$171.233m

$231.095m

Assets

$59.862m

Liabilities

$24.107m

Debt
Debt to Assets

10.4%

0.3x

Debt to EBITDA
Free Cash Flow

-$82.360m

-40.9%

1y CAGR

-27.7%

3y CAGR

-11.4%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.